To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.
All releases
English
Initiator Pharma receives CTA approval for IPTN2021 program Phase I study to assess pain reducing effects
Initiator Pharma A/S, a clinical-stage pharma company, announced today that it has received approval of a Clinical Trials Application for its planned Phase I study in the IPTN2021 program with the drug substance IP2015 in healthy subjects challenged with pain inducing ingredient (capsaicin).
Trading of Initiator Pharma shares on Nasdaq First North Growth market starts today
Initiator Pharma A/S, a clinical-stage Life Sciences company, announced today, October 25, 2021, first trading day at Nasdaq First North Growth Market and new website.
Initiator Pharma A/S has been approved for listing on the Nasdaq First North Growth Market
Initiator Pharma A/S (“Initiator” or “the Company”) has today received approval for admission to trading on the Nasdaq First North Growth Market. The first day of trading on Nasdaq First North…
Correction of previously published press release regarding CTA-filing for Phase I study
The press release published by Initiator Pharma at 03:52 p.m. today, October 19, 2021, “Initiator Pharma files CTA for Phase I study with IP2105 in relation to assessment of pain reducing effects…
Initiator Pharma files CTA for Phase I study with IP2105 in relation to assessment of pain reducing effects
Initiator Pharma A/S, a clinical-stage Life Sciences company, announced today that it has filed a Clinical Trials Application for its planned Phase I study with IP2105 in healthy subjects challenged…
Initiator Pharma A/S publishes information memorandum in connection with the change of listing to Nasdaq First North Growth Markets
On Monday October 7, 2021 Nasdaq Stockholm AB approved Initiator Pharma A/S (“Initiator Pharma” or the “Company”) application for admission to trading of the Company’s shares on Nasdaq…
Initiator Pharma A/S receives conditional approval for listing of its shares on to Nasdaq First North Growth Market in Stockholm
Initiator Pharma A/S (“Initiator Pharma” or “the Company”) has applied for and received conditional approval for admission to trading of its shares on Nasdaq First North Growth Market Stockholm…
Result of incentive program in Initiator Pharma A/S
The AGM held on May 28, 2021 approved a long-term incentive program (“LTI2021”) for key personnel and board members. Under this program the board is authorized to allow participants in the…
Initiator Pharma includes the first patient in Phase 2b study with IPED2015 in Erectile Dysfunction patients
Initiator Pharma A/S, a clinical-stage life science company, announced today that it has dosed the first patient in the Phase 2b study in Erectile Dysfunction (ED) patients with the drug candidate…